Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
extension tags : Genetown save search
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
Published: 2024-03-21 (Crawled : 12:30) - biospace.com/
CRL | News | $240.13 3.26% 0.0% 610K
|
Commercial Services
|
| O: 0.68%
H: 1.71%
C: 1.27%
extension therapy
ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease
Published: 2023-09-12 (Crawled : 12:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
disease series extension program therapeutics
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
Published: 2022-10-12 (Crawled : 12:00) - biospace.com/
FULC | $7.445 2.69% 2.62% 510K
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: -5.0%
label extension canada therapeutics study phase 2
Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases
Published: 2022-07-06 (Crawled : 16:00) - biospace.com/
AMLX A | $1.945 -1.77% -1.8% 1.5M
|
|
| O: 3.28%
H: 13.11%
C: 2.23%
amx0035 label extension als trial international
Rhythm Pharmaceuticals Presents New Data from Long-term Extension Trial Evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR Deficiency Obesity at ENDO 2022
Published: 2022-06-13 (Crawled : 13:00) - biospace.com/
RYTM A | $39.945 2.4% 2.34% 410K
|
Health Technology
|
| O: -12.41%
H: 0.0%
C: -8.38%
obesity extension trial setmelanotide
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
Published: 2022-06-03 (Crawled : 12:20) - biospace.com/
AMLX A | $1.945 -1.77% -1.8% 1.5M
|
|
| O: 36.13%
H: 4.81%
C: -7.14%
amx0035 treatment pdufa als
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
Published: 2022-04-04 (Crawled : 12:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.2%
H: 0.26%
C: -3.28%
drug application review
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome
Published: 2022-02-24 (Crawled : 18:00) - biospace.com/
RYTM A | $39.945 2.4% 2.34% 410K
|
Health Technology
|
| O: -10.16%
H: 1.13%
C: -3.46%
imcivree fda als setmelanotide set pdufa syndros
Insulet’s Omnipod® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control With One Year of Use
Published: 2021-09-30 (Crawled : 12:00) - biospace.com/
PODD | $167.18 1.68% 1.65% 550K
|
Health Technology
|
| O: 0.12%
H: 2.82%
C: 1.76%
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.